ENTA
ENANTA PHARMACEUTICALS INC
-0.07 (-0.55%)12.63USD109K成交股數368M市值–本益比(近四季)5.6股價營收比-21.6%營收年增(近四季)2026-11-16下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 9 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 14.4M-4% | 17.2M+1% | 18.6M+27% | 18.3M+2% | 14.9M-12% | 17.0M-6% | 14.6M-23% | 18.0M+1% | 17.1M | 18.0M | 18.9M | 17.8M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 22.1M | 19.4M | 20.9M | 27.2M | 28.1M | 27.7M | 30.8M | 28.7M | 35.6M | 36.4M | 43.0M | 43.5M |
| 銷售管理費用 | 9.5M | 9.6M | 9.0M | 10.0M | 11.4M | 12.8M | 13.7M | 13.4M | 14.2M | 16.5M | 12.6M | 13.8M |
| 營業利益 | −17.2M-30% | −11.9M-50% | −11.3M-62% | −18.9M-22% | −24.5M-25% | −23.5M-33% | −29.9M-19% | −24.2M-39% | −32.8M | −34.9M | −36.7M | −39.5M |
| 營業利益率 | -120.0% | -69.1% | -60.5% | -103.2% | -164.3% | -138.8% | -204.4% | -134.6% | -192.1% | -193.8% | -194.3% | -221.7% |
| 稅後淨利 | −19.5M-14% | −13.1M-41% | −11.9M-59% | −18.3M-19% | −22.6M-27% | −22.3M-33% | −28.8M-26% | −22.7M-40% | −31.2M | −33.4M | −39.1M | −37.7M |
| 淨利率 | -135.8% | -76.3% | -64.1% | -99.7% | -151.7% | -131.4% | -197.3% | -126.1% | -182.7% | -185.6% | -206.8% | -211.6% |
| 稀釋 EPS | -0.67-37% | -0.45-57% | -0.42-69% | -0.85-21% | -1.06-28% | -1.05-34% | -1.36-27% | -1.07-40% | -1.47 | -1.58 | -1.86 | -1.79 |
| 稀釋股數 | 29.1M | 29.0M | 28.7M | 21.4M | 21.4M | 21.2M | 21.2K | 21.2M | 21.2M | 21.1M | 21.1M | 21.0M |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 33.4M | 34.9M | 37.4M | 44.8M | 60.2M | 84.3M | 37.2M | 35.8M | 63.5M | 39.9M | 95.2M | 73.2M |
| 應收帳款 | 6.5M | 7.8M | 8.5M | 8.3M | 6.8M | 7.7M | 6.6M | 8.2M | 7.8M | 8.2M | 18.9M | 17.8M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 297M | 315M | 330M | 301M | 323M | 349M | 377M | 399M | 414M | 428M | 495M | 326M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 196M | 198M | 203M | 222M | 229M | 237M | 248M | 250M | 247M | 237M | 257M | 57.1M |
| 股東權益 | 101M | 117M | 127M | 79.3M | 93.5M | 112M | 129M | 149M | 166M | 192M | 238M | 269M |
| 負債比 | 66.0% | 63.0% | 61.6% | 73.7% | 71.0% | 67.9% | 65.8% | 62.7% | 59.8% | 55.2% | 52.0% | 17.5% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −11.7M | – | – | −16.8M-33% | – | – | – | −25.0M | – | – |
| 資本支出 | – | – | 143K | – | – | 8.7M | – | – | – | 787K | – | – |
| 自由現金流 | – | – | −11.8M | – | – | −25.5M-1% | – | – | – | −25.8M | – | – |
| 折舊攤銷 | – | – | 1.2M | – | – | 889K | – | – | – | 642K | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | -63.6% | – | – | -150.6% | – | – | – | -143.2% | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 65.3M
| Royalty | 65.3M | 100.0% | -3.4% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 65.3M | -3.4% | −81.9M | -125.4% | -3.84 | −32.2M |
| FY2024 | 67.6M | -14.6% | −116M | -171.6% | -5.48 | −96.7M |
| FY2023 | 79.2M | -8.1% | −134M | -169.0% | -6.38 | −112M |
| FY2022 | 86.2M | -11.2% | −122M | -141.3% | -5.91 | −86.9M |
| FY2021 | 97.1M | -20.7% | −79.0M | -81.4% | -3.92 | −70.7M |
| FY2020 | 122M | -40.3% | −36.2M | -29.5% | -1.81 | 5.6M |
| FY2019 | 205M | -0.7% | 46.4M | 22.6% | 2.21 | 66.0M |
| FY2018 | 207M | – | 72.0M | 34.8% | 3.48 | 26.2M |